Update shared on 23 Sep 2025
Fair value Increased 5.53%The consensus Analyst Price Target for Basilea Pharmaceutica has increased to CHF90.42, reflecting a higher future P/E multiple despite slightly lower forecast revenue growth.
What's in the News
- Basilea raised full-year 2025 revenue guidance to CHF 225 million (up 8%) but lowered expected operating result to CHF 50 million from CHF 62 million.
- Initiated FORWARD-IM, a phase 3 registrational study for broad-spectrum antifungal fosmanogepix, targeting invasive mold infections in adults; study managed by PSI CRO AG, partially funded by BARDA, and with Pfizer retaining first negotiation rights.
- BARDA committed an additional USD 39 million (total USD 68 million to date) toward development of fosmanogepix and BAL2062, under an OTA potentially providing up to USD 268 million in non-dilutive funding over 12 years, covering roughly 60% of project costs.
Valuation Changes
Summary of Valuation Changes for Basilea Pharmaceutica
- The Consensus Analyst Price Target has risen from CHF85.68 to CHF90.42.
- The Future P/E for Basilea Pharmaceutica has significantly risen from 14.82x to 16.39x.
- The Consensus Revenue Growth forecasts for Basilea Pharmaceutica has fallen slightly from 10.1% per annum to 9.7% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.